Finnish Healthcare Companies Deliver Stability Amid U.S. Uncertainty

According to Finnish Customs, health technology exports to the United States totaled EUR 856 million in 2024, making it Finland’s largest market. Germany ranked second with exports worth EUR 265 million, followed by China at EUR 157 million.  

“Despite the uncertainty, our customers continue to focus primarily on the U.S. market,” says Tarja Enala, Head of the Health 360 Finland Program at Business Finland. “The uncertainty stems from potential tariffs on medical devices and other health products.” According to Enala, such measures could have a significant impact and put pressure on companies to restructure their supply chains. 

On the other hand, Senior Advisor Titta Houni from Business Finland's New York office says that the Trump administration aims to deregulate health technology to promote innovation and efficiency.  

“The administration’s key actions include repealing rules it deems unnecessary, speeding up approval processes, promoting remote healthcare and artificial intelligence, and streamlining control structures. This policy supports market access, but naturally also raises concerns about patient safety and data protection,” Houni comments. 

The world's best hospital is interested in Finnish expertise 

AMPlify is a US-based program aimed at especially young, growth-oriented Finnish companies that supports access to the US healthcare market. Through AMPlify, companies can get help with difficulties with regulation, testing, or registration – or aim for long-term partnerships.  It has chosen the Mayo Clinic as its partner, which has been voted the best hospital in the world eight times in a row.  

“The United States is our most important market, where our current customer base consists primarily of pharmaceutical companies and research organizations. Our next goal is to open the door to the clinical laboratory market for our CE marked kit, which we have just begun manufacturing in California. This is one example of where the cooperation with the Mayo Clinic, visibility, and contacts at events play a key role,” says Jari Närhi, CEO and founder of NADMED Oy. 

 25 companies participated in the call that ended this spring, 11 of which were selected: Algorithmiq, Arivin Therapeutics, Biohit, Genomill Health, MultivisionDx, NADMED, Orbican, Orcason Medical, Otos Health, SoihtuDTx and Vitalsigns.  

Another example of the Health 360 Finland program’s support for Finnish companies in the U.S. health sector is the opportunity to participate in the Finland Pavilion at one of the world’s leading health conferences. HLTH USA brings together more than 12,000 experts, investors, and policymakers from across the globe.  

The following companies from Finland will participate in this year’s HLTH USA 2025 health sector event in Las Vegas on October 20-22, 2025: Buddy Healthcare, Business Oulu, CleverHealth Network, Curify Labs, Kiwecare / Smart PD Solutions, Koite Health, Moncyte Health, NADMED, Otos Health, Peilivision, Klinik AI, Soundless and Solid IO. 

Kiwecare CEO Juha Remahl believes that the US will remain the main growth area, despite the political climate: 

“We are developing a system for real-time, AI-based remote monitoring of peritoneal dialysis and early detection of peritonitis. In the United States, our focus is on understanding national requirements and working with a significant local player. Data-driven patient safety and possible deregulation support our entry to the market.” 

Did you know: Last year, Business Finland funded health-related projects last year with more than EUR 65 million; in 2023 the funding was EUR 58 million. This year's goal is to grant more than EUR 65 million in funding for innovations and new solutions in the health sector.